Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $492.77M
• Dividend Yield: N/A
• Average Volume (3M): 1.22M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: 13.17%
• EPS Growth: 64.50%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 381,995,120
• 10 Day Avg. Volume: 1,155,288
• 30 Day Avg. Volume: 1,216,439
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 1.61
• Enterprise Value/Gross Profit: 3.71
• Enterprise Value/Ebitda: -2.72
• 1Y Price Target: $1.55
• Price Target Upside: 19.23% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $1.50 ▲(15.38% Upside)

The overall stock score is primarily impacted by the company's financial struggles, including declining revenues and negative profit margins. While technical indicators and corporate events provide some positive aspects, the valuation remains unattractive due to negative earnings.

Positive Factors

Financial Performance

LAB reported 1Q revenue slightly better than consensus estimates, which is a good result in light of ongoing macro pressures and share weakness.

Operational Improvement

Solid operational expense controls showcase operational improvement despite gross margin miss due to mix and volume.

Negative Factors

Growth Outlook

The sale of SomaLogic has led to a lower growth outlook for Standard Biotools Inc.

Market Exposure

There is a higher exposure to ongoing market headwinds, including US Academic funding and soft capital expenditure trends.

Near-term Catalysts

Fewer near-term catalysts are available to drive shares higher following the sale of SomaLogic.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools (LAB) is a biotechnology company that specializes in developing innovative tools and technologies for genomic analysis. The company operates primarily in the life sciences sector, providing products and services designed for researchers in genomics, proteomics, and cellular analysis. Standard BioTools' core offerings include advanced sequencing technologies, microfluidic devices, and software solutions that facilitate high-throughput data generation and analysis, empowering scientists to make breakthroughs in personalized medicine and biological research.

How the Company Makes Money

Standard BioTools generates revenue through multiple key streams, primarily by selling its proprietary laboratory instruments, consumables, and software solutions to research institutions, pharmaceutical companies, and clinical laboratories. The company also benefits from ongoing service contracts and maintenance agreements for its equipment, which provide a steady revenue flow. Additionally, Standard BioTools engages in strategic partnerships with academic institutions and industry players, allowing for collaborative research efforts that can lead to innovative product development and expanded market reach. These partnerships often include licensing agreements, which can further enhance the company's revenue potential.

Standard BioTools Financial Statement Overview

Summary

The company faces significant financial challenges with declining revenues and negative profit margins. Despite a low debt-to-equity ratio, profitability and cash flow are under pressure.

Income Statement

The income statement reveals a challenging financial situation with declining revenues and negative profit margins. The TTM data shows a revenue decline of 9.1%, and the net profit margin is significantly negative at -78.1%. Gross profit margin has decreased to 43.3% from 48.3% in the previous year. The company is struggling with profitability as indicated by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.067, indicating low leverage, which is a positive aspect. However, the return on equity is negative at -26.2%, reflecting poor profitability. The equity ratio is not explicitly calculated, but the company maintains a strong equity position relative to its assets.

Cash Flow

Cash flow analysis highlights negative operating and free cash flows, with a free cash flow growth rate of -14.9% TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is above 1, suggesting that free cash flow exceeds net income, which is a positive sign.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	154.24M	174.43M	106.34M	97.95M	130.58M	138.14M
Gross Profit	66.84M	84.26M	50.45M	37.05M	69.37M	83.33M
EBITDA	-91.35M	-118.14M	-54.46M	-173.57M	-43.77M	-32.59M
Net Income	-120.50M	-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet
Total Assets	556.97M	612.34M	323.07M	390.31M	275.21M	324.76M
Cash, Cash Equivalents and Short-Term Investments	237.09M	292.87M	114.89M	165.78M	28.45M	68.52M
Total Debt	28.62M	33.00M	98.21M	102.66M	111.65M	95.38M
Total Liabilities	132.43M	140.62M	159.87M	471.78M	180.62M	185.71M
Stockholders Equity	424.54M	471.72M	163.20M	229.79M	94.60M	139.05M
Cash Flow
Free Cash Flow	-105.46M	-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
Operating Cash Flow	-92.88M	-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
Investing Cash Flow	36.97M	363.17M	20.24M	-88.13M	-11.95M	39.98M
Financing Cash Flow	-54.46M	-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Positive. The current price of 1.3 is above the 20-day moving average (MA) of 1.27, above the 50-day MA of 1.30, and below the 200-day MA of 1.35, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.14 is Neutral, neither overbought nor oversold. The STOCH value of 63.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	63 Neutral	$672.79M	―	-4.54%	―	4.31%	69.57%
CSTL	59 Neutral	$669.80M	30.59	-2.15%	―	20.40%	-165.41%
MYGN	52 Neutral	$631.77M	―	-70.03%	―	3.83%	-137.31%
PSNL	52 Neutral	$451.37M	―	-60.26%	―	0.36%	22.13%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
LAB	48 Neutral	$492.77M	―	-22.40%	―	13.17%	64.50%
OPK	48 Neutral	$1.10B	―	-13.16%	―	-7.31%	29.84%

Standard BioTools Corporate Events

Standard BioTools Announces Strategic Restructuring Plan

On August 28, 2025, Standard BioTools Inc. announced a strategic restructuring plan to consolidate its R&D capabilities from South San Francisco to its Singapore facility, aligning with its manufacturing operations. This move, aimed at enhancing operational efficiency and reducing costs, involves a reduction-in-force affecting U.S. employees and is expected to incur expenses of approximately $3.6 million, with potential for additional costs due to unforeseen events.

Standard BioTools Announces SomaLogic Sale to Illumina

Standard BioTools reported its financial results for the second quarter of 2025, highlighting a total revenue of $42 million, with $21.8 million from continuing operations. The company announced the strategic sale of SomaLogic to Illumina for up to $425 million, expected to close in the first half of 2026, which will significantly bolster its cash reserves to at least $550 million. This move is part of a broader strategy to streamline operations and focus on profitability by 2026, despite challenges such as reduced U.S. academic spending and global capital constraints. The company is pausing its earnings calls temporarily to focus on operational adjustments.

Standard BioTools Approves Stock Awards for Executives

On July 29, 2025, Standard BioTools Inc. announced that its Board of Directors approved restricted stock unit retention awards for its President & CEO, Michael Egholm, and CFO, Alex Kim, effective August 1, 2025. These awards, part of the company’s 2011 Equity Incentive Plan, aim to retain key executives by offering significant stock incentives contingent on continued employment. Additionally, the Human Capital Committee approved an increase in Mr. Kim’s annual performance bonus target to 80% of his base salary, effective January 1, 2025, highlighting the company’s commitment to rewarding its leadership.

Standard BioTools Sells Subsidiaries to Illumina

On June 22, 2025, Standard BioTools Inc. announced a strategic sale of its subsidiaries, including SomaLogic, to Illumina, Inc. for up to $425 million. This transaction aims to simplify Standard BioTools’ operations, achieve adjusted EBITDA break-even, and retain strategic upside through royalties and commercialization rights. The deal reflects improvements made to the business and aligns with the company’s focus on profitability and long-term value creation.

Standard BioTools Approves Equity Plan Amendment at Meeting

Standard BioTools Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025, where stockholders approved an amendment to the company’s Amended and Restated 2011 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance by 17,400,000 shares. Additionally, the election of Class III directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm were also confirmed during the meeting.